OPIS
OPIS is an international CRO providing clinical trial execution, sample analysis coordination, and regulatory support for biopharmaceutical companies across Asia, Europe, and the Americas, and also publishes refined fuels and energy market price assessments and analytics.
- Company typePrivate
- Founded1998
- HeadquartersDesio, Italy
- Headcount251–500
- GTM typeB2B
- OfferingServices
What OPIS does
OPIS is a private international contract research organization (CRO) founded in 1998, headquartered in Desio, Italy, with 251-500 employees and the web domain opisresearch.com. Its core business delivers clinical trial execution, sample analysis coordination, and regulatory support to biopharmaceutical companies across Asia, Europe, and the Americas, with stated presence in the Asia-Pacific region via partnerships in South Korea (GCCL) and Hong Kong (Immuno Cure, HKSTP delegation). Beyond clinical research, OPIS is also associated with energy commodity market intelligence, providing price assessments, market news, and analytics for refined fuels, marine fuels, feedstocks, LPG, and jet fuels across global regions for refiners, traders, and energy market participants.
The company operates a direct B2B go-to-market in both lines, relying on industry conferences such as the J.P. Morgan Healthcare Conference as primary partnership and business development channels. Strategic ecosystem build-out is central: in 2026 OPIS signed an MOU with GCCL at JPM Healthcare 2026, joined the Orphan Therapeutics Accelerator's Orphan ClinDevNet alongside partners SK pharmteco (U.S. viral vector manufacturing), Uniphar (expanded access), and TMC Pharma (UK/EU regulatory and market access), and formed an overseas clinical trial execution partnership with Immuno Cure at BIO 2026 in San Diego. These moves collectively reposition OPIS from a Europe-anchored CRO into a multi-region, multi-capability platform with explicit ultra-rare disease therapy specialization.
OPIS firmographics
Firmographics- Name
- OPIS
- Legal name
- OPIS
- Website
- https://opisresearch.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- OPIS is an international CRO providing clinical trial execution, sample analysis coordination, and regulatory support for biopharmaceutical companies across Asia, Europe, and the Americas, and also publishes refined fuels and energy market price assessments and analytics.
- Ownership category
- akta.pro rank
OPIS industry classification
Industry- Product category
- Contract Research Organization (CRO) / Clinical Research Services
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where OPIS is headquartered
LocationHeadquarters
- HQ city
- Desio
- HQ country
- Italy
- HQ region
- Europe
Markets served
OPIS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Distribution channels1 record
Marketing channels1 record
OPIS product offering
Product offeringCore offering
OPIS operates two distinct business lines: (1) a global Contract Research Organization (CRO) delivering clinical trial execution, sample analysis coordination, and regulatory support for biopharmaceutical companies across Asia, Europe, and the Americas; and (2) an energy commodity pricing and analytics service providing market news, price assessments, and analytics for refined fuels, marine fuels, feedstocks, LPG, and jet fuels across global regions.
Product overview
OPIS operates as a dual business entity offering two distinct product lines: (1) OPIS as a global contract research organization providing clinical trial services, combining GCCL's clinical trial analysis expertise with OPIS's Europe-focused global network to deliver integrated solutions for biopharmaceutical companies across Asia, Europe, and the Americas; and (2) OPIS as an energy commodity pricing and analytics service providing refined fuels market news, price assessments, and analytics for refined fuels, marine fuels, feedstocks, LPG, and jet fuels across global regions.
Differentiator
Problem solved
Functional benefit
Products and services
- OPIS Clinical Trial Services A global contract research organization (CRO) providing clinical trial execution, sample analysis coordination, and regulatory support services for biopharmaceutical companies across Asia, Europe, and the Americas. The service combines partner analysis expertise with OPIS's Europe-focused global network to deliver integrated clinical trial solutions.
- Refined Fuels Market Intelligence Market news, price assessments, and analytics for refined fuels, marine fuels, feedstocks, LPG, and jet fuels across various global regions, supporting refiners, traders, and energy market participants in making informed decisions amid evolving energy market challenges.
Companies that use OPIS
Customer profileSegments3 records
Ideal customer profiles3 records
OPIS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
OPIS partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major and core.
- Immuno CuremajorImmuno Cure partnered with OPIS for overseas clinical trial execution as part of HKSTP's delegation to BIO 2026. The partnership enables Immuno Cure to leverage OPIS's global clinical trial execution capabilities for international market expansion.
- GCCL (GCC Clinical & Toxicology Lab Co., Ltd.)majorGCCL, a South Korea-based clinical trial sample analysis provider, and OPIS signed a Memorandum of Understanding at the J.P. Morgan Healthcare Conference 2026 in San Francisco. The partnership combines GCCL's clinical trial analysis expertise with OPIS's Europe-focused global network to deliver integrated solutions for biopharmaceutical companies across Asia, Europe, and the Americas.
- Orphan Therapeutics Accelerator (OTXL)coreOPIS joined Orphan ClinDevNet, the Orphan Therapeutics Accelerator's development network, adding targeted capabilities for clinical trial execution to help overcome barriers that cause ultra-rare disease therapies to stall. The expansion provides a decentralized, outsourced infrastructure for development and commercialization.
- UnipharcoreUniphar joined Orphan ClinDevNet as a strategic partner alongside OPIS, adding expanded access programs capabilities to the network for ultra-rare disease therapy development.
- SK pharmtecocoreSK pharmteco joined Orphan ClinDevNet as a strategic partner alongside OPIS, contributing U.S.-based viral vector manufacturing capabilities to the network.
- TMC PharmacoreTMC Pharma joined Orphan ClinDevNet as a strategic partner alongside OPIS, providing UK/European regulatory and market access expertise to the network.
Recent moves3 records
Expansion highlights3 records
OPIS competitors and assessment
Company assessmentDirect peers
- Parexel International: Parexel is a global mid-to-large CRO with deep therapeutic specialization; it directly competes with OPIS for biopharma clinical trial engagements and shares overlap with OPIS's specialty therapeutic-area positioning.
- Fortrea (formerly Labcorp Drug Development): Fortrea is a focused CRO spun out of Labcorp, offering Phase I–IV clinical trial services comparable to OPIS's CRO franchise, and competes directly for biopharma outsourcing contracts across Europe, Asia, and the Americas.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-tier global CRO focused on complex therapeutic areas—including rare and specialty indications—closely matching OPIS's specialty and ultra-rare disease positioning.
- Syneos Health: Syneos Health is a fully integrated biopharma solutions and clinical CRO competing head-to-head with OPIS for outsourced clinical execution and biopharmaceutical sponsor relationships.
- IQVIA: IQVIA is the largest global CRO and clinical services provider, directly comparable to OPIS across therapeutic clinical trial execution, biopharma services, and global site/network management—a benchmark competitor for any full-service CRO mandate.
- ICON plc: ICON is a global CRO providing full-service clinical development, lab, and post-approval services—directly comparable to OPIS for biopharma clinical trial execution and the type of mega-program work OPIS is targeting.
- Medpace Holdings: Medpace is a mid-sized, therapeutically focused CRO executing global Phase I–IV trials—directly comparable to OPIS in scale, therapeutic specialization, and biopharma client base.
- Argus Media: Argus Media is a leading independent provider of price benchmarks, analytics, and market intelligence for refined fuels, LPG, and jet fuels—directly comparable to OPIS's refined fuels market intelligence product line.
Broad incumbents
- Charles River Laboratories: Charles River is a broad life-sciences services incumbent that includes clinical and safety/CRO offerings alongside preclinical and manufacturing—comparable to OPIS as a scaled clinical services competitor with deeper breadth.
Emerging players
- BioAgilytix: BioAgilytix is a specialized bioanalytical and immunology CRO—comparable to the GCCL analytical capability OPIS is integrating—to the extent OPIS is building a sample-analysis-coordinated clinical offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
OPIS social profiles
Digital presenceOPIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
OPIS leadership team
Management profileNumber of profiles
Profiles1 record
OPIS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OPIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OPIS
What does OPIS do?
OPIS operates two distinct business lines: (1) a global Contract Research Organization (CRO) delivering clinical trial execution, sample analysis coordination, and regulatory support for biopharmaceutical companies across Asia, Europe, and the Americas; and (2) an energy commodity pricing and analytics service providing market news, price assessments, and analytics for refined fuels, marine fuels, feedstocks, LPG, and jet fuels across global regions.
Is OPIS a public or private company?
OPIS is a private company. It is classified as unknown and is currently operating.
When was OPIS founded?
OPIS was founded in 1998. It employs 251 to 500 people.
Where is OPIS based?
OPIS is headquartered in Desio, Italy, in the Europe region.
Who are OPIS's main competitors?
Direct peers on record are Parexel International, Fortrea (formerly Labcorp Drug Development), Worldwide Clinical Trials, Syneos Health, IQVIA, ICON plc, Medpace Holdings and Argus Media. Charles River Laboratories is listed as a broad incumbent. BioAgilytix is listed as an emerging player.
Does OPIS have an API?
No public API is recorded for OPIS.
What industry is OPIS in?
OPIS's product category is Contract Research Organization (CRO) / Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease).